Almost two years with COVID-19: some aspects of antibiotic use | CMAC

Almost two years with COVID-19: some aspects of antibiotic use

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):248-253

​ Ortenberg E.A.
10.36488/cmac.2021.3.248-253
COVID-19 antibiotics efficacy resistance
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):248-253

Abstract

The objective of this review was to summarize impact of the widespread administration of antibiotics in treatment algorithms for patients with COVID-19 on treatment outcomes. The experience of antimicrobial use agents during COVID-19 pandemic did not show any life-saving effect. It justifies a need to limit their administration to COVID-19 patients.

Eduard A. Ortenberg

Tyumen State Medical University, Tyumen, Russia

  • 1. Ginsburg A.S., Klugman K.P. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Health. 2020;8(12):e1453-e1454. DOI: 10.1016/S2214-109X(20)30444-7
  • 2. Mahoney A.R., Safaee M.M., William M., Wuest W.M., Furst A. The silent pandemic: emergent antibiotic resistances following the global response to SARS-CoV-2. iScience. 2021;102304. DOI: 10.1016/j.isci.2021.102304
  • 3. Interim methodological recommendations. Prevention, diagnostics and treatment of new coronavirus infection (COVID-19). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID19_%28v.10%29-08.02.2021_%281%29.pdf Russian.
  • 4. Drożdżal S., Rosik J., Lechowicz K., Machaj F., Kotfis K., Ghavamiet S., et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020;53:100719. DOI: 10.1016/j.drup.2020.100719
  • 5. Trivedi N., Verma A., Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020;24(23):12593-12608. DOI: 10.26355/eurrev_202012_24057
  • 6. Shah R.R. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. J Clin Pharm Ther. 2021;46(1):17-27. DOI: 10.1111/jcpt.13267
  • 7. Bassetti M., Giacobbe D.R., Aliberti S., Barisione E., Centanni S., De Rosa F., et al. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020;26(7):880-894. DOI: 10.1016/j.cmi.2020.04.031
  • 8. Peng X., Xu X., Li Y., Cheng L., Zhou X., Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9. DOI: 10.1038/s41368-020-0075-9
  • 9. Lippi G., Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190-191. DOI: 10.1016/j.cca.2020.03.004
  • 10. Ruuskanen O., Lahti E., Jennings L.C., Murdoch D.R. Viral pneumonia. Lancet. 2011;377(9773):12641275. DOI: 10.1016/s01406736(10)61459-6
  • 11. Klein E.Y., Monteforte B., Gupta A., Jiang W., May L., Hsieh Y., Dugas A. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10(5):394-403. DOI: 10.1111/irv.12398
  • 12. Chen N., Zhou M., Dong X., Qu J., Gong F., Hanet Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. DOI: 10.1016/s0140-6736(20)30211-7
  • 13. Zhang G., Hu C., Luo L., Fang F., Chen Y., Liet J., et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. DOI: 10.1016/j.jcv.2020.104364
  • 14. Rawson T.M., Moore L., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-2468. DOI: 10.1093/cid/ciaa530
  • 15. Kim Y.G., Park J.H., Reimer T., Baker D.P., Kawai T., Kumar H., et al. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe. 2011;9:496-507. DOI: 10.1016/j.chom.2011.05.006
  • 16. Lai C.C., Wang C.Y., Hsueh P.R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53(4):505-512. DOI: 10.1016/j.jmii.2020.05.013
  • 17. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. DOI: 10.1016/s0140-6736(20)30566-3
  • 18. Huttner B., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-810. DOI: 10.1016/j.cmi.2020.04.024
  • 19. Hughes S., Troise O., Donaldson H., Mughal N., Moore L. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26:1395-1399. DOI: 10.1016/j.cmi.2020.06.025
  • 20. Garcia-Vidal C., Sanjuan G., Moreno-García E., PuertaAlcalde P., Garcia-Pouton N., Chumbita M., et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83-88. DOI: 10.1016/j.cmi.2020.07.041
  • 21. Langford B.J., So M., Raybardhan S., Leung V., Soucy J.P., Westwoodet D., et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis .Clin Microbiol Infect. 2021;27(4):520-531. DOI: 10.1016/j.cmi.2020.12.018
  • 22. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. National Institute for Health and Care Excellence (NICE), 2020. Available at: www.nice.org.uk/guidance/ng173/chapter/4-Assessing-the-ongoing-needforantibiotics.
  • 23. Zaitsev A.A. Letter to the editors. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2020;22(2):84-86. Russian. DOI: 10.36488/cmac.2020.2.84-86
  • 24. World Health Organization. Clinical management of COVID-19 interim guidance, May 2020. Geneva: World Health Organization; 2020. Available at: www.who.int/publications-detail/clinical-management-of-covid-19.
  • 25. Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFaddenet D., et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622-1629. DOI: 10.1016/j.cmi.2020.07.016
  • 26. Huang C., Soleimani J., Herasevich S., Pinevich Y., Pennington K., Dong Y., et al. Clinical characteristics, treatment, and outcomes of critically ill patients with COVID-19: a scoping review. Mayo Clin Proc. 2021;96(1):183-202. DOI: 10.1016/j.mayocp.2020.10.022
  • 27. Chjng W.H., Saha B.K., Ramani A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection. 2021;1-15. DOI: 10.1007/s15010-021-01602-z
  • 28. Sieswerda E., de Boer M., Bonten M., Boersma W., Jonkers R., Alevaet R., et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27(1):61-66. DOI: 10.1016/j.cmi.2020.09.041
  • 29. Nair G.B., Niederman M.S. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021;217:107663. DOI: 10.1016/j.pharmthera.2020.107663
  • 30. Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI: 10.1164/rccm.201908-1581ST
  • 31. Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949
  • 32. Mehra M., Desai S., Ruschitzka F., Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;S0140-6736(20)31180-6. DOI: 10.1016/S0140-6736(20)31180-6
  • 33. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from in vitro antiinflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;68:479-503. DOI: 10.1007/s00228-011-1161-x
  • 34. Firth A., Prathapan P. Azithromycin: the first broad-spectrum therapeutic. Eur J Med Chem. 2020;207:112739. DOI: 10.1016/j.ejmech.2020.112739
  • 35. Albani F., Fusina F., Giovannini A., Ferretti P., Granato A., Prezioso C., et al. Impact of azithromycin and/or hydroxychloroquine on hospital mortality in COVID-19. J Clin Med. 2020;9:2800. DOI: 10.3390/jcm9092800
  • 36. Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S., Rivera D., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907-1918. DOI: 10.1016/S0140-6736(20)31187-9
  • 37. Furtado R.H., Berwanger O., Fonseca H.A., Corrêa T.D., Ferraz L.R., Lapa M.G., et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959-967. DOI: 10.1016/S0140-6736(20)31862-6
  • 38. Rosenberg E.S., Dufort E.M., Udo T., Wilberschied L.A., Kumar J., Tesoriero J., et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493-2502. DOI: 10.1001/jama.2020.8630
  • 39. Gyselinck I., Janssens W., Verhamme P., Vos R.B. Rationale for azithromycin in COVID-19: an overview of existing evidence. MJ Open Respir Res. 2021;8(1):e000806. DOI: 10.1136/bmjresp-2020-000806
  • 40. Sarayani A., Cicali B., Henriksen C., Brown J. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. 2021;17(2):483-486. DOI: 10.1016/j.sapharm.2020.04.016
  • 41. Michaud V., Dow P., Sweilem B., Deodhar M., Arwood M., Cicali B., Turgeon J. Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2021;14(1):20-28. DOI: 10.1111/cts.12882
  • 42. Zhang J., Ma X., Yu F., Liu J., Zou F., Pan T., Zhang H. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020.02.05.935387. DOI: 10.1101/2020.02.05.935387
  • 43. Mosquera-Sulbaran J.A., Hernández-Fonseca H. Tetracycline and viruses: a possible treatment for COVID-19? Arch Virol. 2021;166(1):1-7. DOI: 10.1007/s00705-020-04860-8
  • 44. Huttner B.D., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! J Clin Microbiol Infect. 2020;26(7):808-810. DOI: 10.1016/j.cmi.2020.04.024
  • 45. Wagner C.E., Prentice J.A., Saad-Roy C.M., Yang L., Grenfell B.T., Levin S.A., Laxminarayan R. Economic and behavioral influencers of vaccination and antimicrobial use. Front Public Health. 2020;8:614113. DOI: 10.3389/fpubh.2020.614113
Views
0 Abstract
0 PDF
0 Crossref citations
Shared